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Paclitaxel- Versus Sirolimus-Eluting Stents for
Unprotected Left Main Coronary Artery Disease
Julinda Mehilli, MD,* Adnan Kastrati, MD,* Robert A. Byrne, MB, MRCPI,* Olga Bruskina, MD,*
Raisuke Iijima, MD,* Stefanie Schulz, MD,* Jürgen Pache, MD,* Melchior Seyfarth, MD,*
Steffen Maßberg, MD,* Karl-Ludwig Laugwitz, MD,† Josef Dirschinger, MD,† Albert Schömig, MD,*†
for the ISAR-LEFT-MAIN (Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for
Unprotected Coronary Left Main Lesions) Study Investigators
Munich, Germany
Objectives The aim of this trial was to compare the safety and efficacy of paclitaxel-eluting stents (PES) and sirolimus-
eluting stents (SES) for treatment of unprotected left main coronary artery (uLMCA) disease.
Background Both PES and SES have reduced the risk of restenosis, particularly in high-risk patient and lesion subsets. How-
ever, their comparative performance in uLMCA lesions is not known.
Methods In this randomized study, 607 patients with symptomatic coronary artery disease undergoing percutaneous coro-
nary intervention for uLMCA were enrolled: 302 were assigned to receive a PES (Taxus, Boston Scientific, Natick,
Massachusetts) and 305 assigned to receive a SES (Cypher, Cordis, Johnson & Johnson, New Brunswick, New
Jersey). The primary end point was the combined incidence of death, myocardial infarction, and target lesion
revascularization (TLR) at 1 year. The secondary end point was angiographic restenosis on the basis of the LMCA
area analysis at follow-up angiography.
Results At 1 year the cumulative incidence of death, myocardial infarction, or TLR was 13.6% in the PES and 15.8% in
the SES group (relative risk [RR]: 0.85, 95% confidence interval [CI]: 0.56 to 1.29, p  0.44). One patient in the
PES group (0.3%) and 2 patients in the SES group (0.7%) experienced definite stent thrombosis (p  0.57). Mor-
tality at 2 years was 10.7% in the PES and 8.7% in the SES group (RR: 1.14, 95% CI: 0.66 to 1.95, p  0.64).
Angiographic restenosis was 16.0% with PES and 19.4% with SES (RR: 0.82, 95% CI: 0.57 to 1.19, p  0.30).
Conclusions Implantation of either PES or SES in uLMCA lesions is safe and effective; both of these drug-eluting stents pro-
vide comparable clinical and angiographic outcomes. (Drug-Eluting-Stents for Unprotected Left Main Stem Dis-
ease [ISAR-LEFT-MAIN]; NCT00133237) (J Am Coll Cardiol 2009;53:1760–8) © 2009 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.035m
c
p
v
t
i
a
t
c
(
cp to 6% of patients with angiographically documented
oronary artery disease present with significant left main
oronary artery lesions (1). They represent a highly relevant
herapeutic issue in view of the large amount of myo-
ardium that is jeopardized if blood flow through the left
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6, 2008, accepted January 6, 2009.ain vessel is critically compromised. Although aorto-
oronary artery bypass graft surgery (CABG) has been the
referred treatment approach, percutaneous coronary inter-
entions (PCIs) are increasingly being used to treat unpro-
ected left main coronary artery (uLMCA) lesions.
See page 1769
Percutaneous intervention with plain balloon angioplasty
n the left main coronary artery (LMCA) was performed on
n infrequent basis in the past but was soon abandoned, due
o suboptimal acute results and high rates of abrupt vessel
losure after the procedure (2). The use of bare-metal stents
BMS) along with the evolution of dual antiplatelet therapy
omprising aspirin and clopidogrel has increased the safety
nd the frequency of application of PCI for treatment of
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May 12, 2009:1760–8 DES for Left Main Coronary Artery LesionsLMCA lesions. However, the use of BMS for this type of
esion has been limited, because of high rates of restenosis
nd frequent need for reintervention (3). In a small ran-
omized study comparing PCI (only 35% of stents im-
lanted being drug-eluting stents [DES]) with CABG for
reatment of uLMCA disease, the need for repeat revascu-
arization at 1 year was 3 times higher for patients under-
oing stenting compared with surgery (4).
DES have considerably reduced the risk of restenosis and
re playing an increasing role in the treatment of various
atient and lesion subsets. Recent evidence has shown that
ES are at least as safe but much more effective in reducing
he need for reintervention, as compared with BMS (5–8).
ith this potential, they might represent a reasonable
reatment option for uLMCA lesions. Although superiority
ver BMS has been demonstrated for a variety of DES,
urrently available and approved DES might not necessarily
e associated with equal performance efficacy (9–11). Po-
ential differences in safety and efficacy between DES might
e of particular import when treating uLMCA lesions.
espite the multitude of comparative DES studies for a
ariety of lesion characteristics, no such study has been
erformed for patients with uLMCA lesions. In fact,
atients with uLMCA lesions have typically been excluded
rom any kind of randomized clinical trials focusing on the
alue of CABG or PCI for the management of coronary
rtery disease. There is increased interest in extending the
emit of PCI with DES to the treatment of uLMCA and in
omparing this method with CABG, which is the recom-
ended treatment approach according to current guidelines
12–14). Whereas surgical methods have been well-
tandardized over the years (15,16), an accurate and compar-
tive evaluation of the relative merits of currently available
ES for this indication might help further optimization of a
CI-based strategy, a necessary step before launching dedi-
ated randomized PCI versus CABG trials in patients with
LMCA disease.
We therefore designed this randomized study to investi-
ate the value of DES in the treatment of uLMCA lesions
y comparing 2 commonly available DES—a paclitaxel-
luting stent (PES) with a sirolimus-eluting stent (SES).
ethods
atient population, randomization, and treatment pro-
ocol. We included patients older than age 18 years with
schemic symptoms or evidence of myocardial ischemia in
he presence of 50% de novo stenosis located in the left
ain stem, provided that written informed consent for
articipation in the study was obtained from the patient or
er/his legally-authorized representative. Exclusion criteria
ere ST-segment elevation myocardial infarction (MI)
ithin 48 h of symptom onset; prior bypass graft surgery;
n-stent restenosis; cardiogenic shock; malignancies or other
omorbid conditions with life expectancy 1 year or that
ight result in protocol noncompliance; left main size4.5 mm; planned staged PCI proce-
ure within 30 days from index
CI; planned elective surgical
rocedure necessitating interrup-
ion of clopidogrel during the
rst 6 months after enrollment;
nown allergy to the study med-
cations: clopidogrel, rapamycin,
aclitaxel, stainless steel, or co-
alt alloy; pregnancy; or previous
nrollment in this trial. The
tudy was conducted in accor-
ance with the provisions of the
eclaration of Helsinki and with
he International Conference on
armonization Good Clinical
ractices, and protocol approval
as obtained from the medical
thics Committee for both par-
icipating centers, the Deutsches
erzzentrum and Medizinische
linik I, Klinikum rechts der
sar, Munich, Germany. All eligible patients were informed
hat CABG is the currently recommended revascularization
trategy and that DES are a new treatment option under
nvestigation for LMCA disease. Patients not suitable for or
nwilling to undergo CABG were considered for participa-
ion in this study.
In each participating center, allocation to treatment, either
ith a PES (TAXUS, Boston Scientific, Natick, Massachu-
etts) or a SES (Cypher, Cordis, Johnson & Johnson, New
runswick, New Jersey), was performed by means of sealed
paque envelopes containing a computer-generated sequence;
his was done immediately after the decision to proceed with
CI. Patients who met all of the inclusion criteria and none of
he exclusion criteria were randomized in the order they
ualified. Patients were allocated to each of the 2 treatment
roups in equal proportions. The treatment groups were
tudied concurrently. Patients were considered enrolled in the
tudy and eligible for the final intention to treat analysis at the
ime of randomization.
Immediately after the decision to perform the interven-
ion, patients were given 500-mg aspirin intravenously and
ntra-arterial or intravenous heparin up to a total amount of
40 U/kg body weight or bivalirudin (intravenous bolus of
.75 mg/kg before the start of the intervention, followed by
nfusion of 1.75 mg/kg/h for the duration of the procedure).
lycoprotein IIb/IIIa inhibitors were given at the discretion
f the operators. The SES was available in sizes of 2.25, 2.5,
.75, 3.0, and 3.5 mm and in lengths of 8, 13, 18, 23, 28,
nd 33 mm; the PES was available in sizes of 2.25, 2.5, 2.75,
.0, 3.5, 4.0, 4.5, and 5.0 mm and in lengths of 8, 12, 16, 20,
4, 28, and 32 mm.
After the intervention, all patients received 150 mg
lopidogrel for the first 3 days. Thereafter they received 75
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  aorto-coronary
artery bypass graft surgery
CI  confidence interval
CK  creatine kinase
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stents(s)
RR  relative risk
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
uLMCA  unprotected left
main coronary arteryg/day clopidogrel and 200 mg/day aspirin indefinitely
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DES for Left Main Coronary Artery Lesions May 12, 2009:1760–8long with other cardiac medications according to the
udgment of the patient’s physician.
Stenting technique to be used was left to the discretion of
he operators. However, use of 2 stents in “culotte” with
nal kissing balloon inflation was the preferred technique
or distal bifurcation lesions.
ollow-up protocol, data management, study end points,
nd definitions. Blood samples were drawn every 8 h for
he first 24 h after randomization and daily thereafter for the
etermination of cardiac markers (creatine kinase [CK],
K-myocardial band, troponin T or I) and blood cell counts
hemoglobin, hematocrit, platelet count, white blood cell
ount). Daily electrocardiographic recordings were per-
ormed until discharge. All patients were evaluated at 30
ays and 12 months as well as yearly thereafter either by
hone or office visit and were monitored throughout the
tudy period for the occurrence of the following clinical
vents: death, MI, stroke, stent thrombosis, and target
esion revascularization (TLR). Repeat coronary angiogra-
hy was scheduled at 6 to 9 months after enrollment in the
tudy. Relevant data were collected and entered into a
pecialized computer database by specialized personnel of
he Clinical Data Management Center. An events commit-
ee blinded to treatment allocation adjudicated all adverse
linical events.
Baseline, post-procedural, and follow-up coronary angio-
rams were digitally recorded and assessed off-line in the
uantitative angiographic core laboratory (ISAR Center,
unich, Germany) with an automated edge-detection sys-
em (CMS version 7.1, Medis Medical Imaging Systems,
eiden, the Netherlands) by 2 independent experienced
perators unaware of the treatment allocation. Quantitative
nalysis was performed on the left main area, which was
onsidered the anatomical coronary region from the left
ain stem ostium to the end of the 5-mm proximal
egments of left anterior descending artery and left circum-
ex artery as well as of ramus intermedius if the latter had a
essel size of more than 2 mm in diameter. The LMCA
tenosis were classified as ostial (stenosis located within 3
m of LMCA ostium), midshaft (stenosis located in the
edial part of LMCA having at least 3 mm of apparently
ondiseased artery before LMCA bifurcation), and distal
stenosis involves the distal part of the LMCA and bifur-
ation/trifurcation with proximal left anterior descending
rtery, proximal left circumflex artery, and proximal ramus
ntermedius if the latter was present).
Patients with a Parsonnet score15 or EuroSCORE6
17,18) were considered high-risk surgical candidates. The
iagnosis of MI required the presence of new significant
waves on the electrocardiogram and/or elevation of
K-myocardial band isoform (or CK if the latter was not
vailable) at least 2 times the upper limit of normal in no
ewer than 2 blood samples. The TLR was defined as any
epeat PCI involving the left main area or CABG involving
t least 1 of the main left coronary vessels due to luminal
enarrowing in the presence of symptoms or objective signs df ischemia. Stent thrombosis was defined according to
cademic Research Consortium criteria (19). Angiographic
inary restenosis was defined as diameter stenosis 50%,
easured by quantitative coronary angiography, in the left
ain area.
The primary end point of the study was the combined
ncidence of all-cause death, MI, and TLR at 1 year after
andomization. The secondary end point was the incidence
f binary angiographic restenosis at follow-up angiography
n the left main area.
ample size calculation and statistical methods. Sample
ize calculation was performed on the basis of the following
ssumption: 1-sided alpha level 0.05, power 80%, primary
nd point rate of 20% with SES on the basis of previously
eported results for DES in similar patients (20), and a
oninferiority threshold of 8% for the PES. Accordingly,
02 patients/group were needed. Two pre-specified analyses
ere planned to be performed in patients with diabetes and
hose with high surgical risk according to Parsonnet score
nd EuroSCORE. All analyses were planned on the basis of
he intention-to-treat principle (i.e., analyses were based on
reatment groups as randomized).
Baseline descriptive statistics are presented as frequencies
nd percentages for categorical variables and mean  SD or
edian (interquartile range) for continuous variables. The
ifferences between the groups were assessed with the
hi-square test or Fisher exact test for categorical data and
tudent t test for continuous data. Survival analysis was
ade by applying the Kaplan-Meier method. Differences in
urvival parameters were assessed for significance, and rel-
tive risks (RRs) were calculated by means of the log-rank
est. The noninferiority hypothesis was formally checked
nly for the primary end point in the overall population. In
his respect, a 1-sided p value 0.05 was considered
ignificant; otherwise, a 2-tailed p value 0.05 was consid-
red to indicate statistical significance. Statistical software
-PLUS version 4.5 (S-PLUS, Insightful Corp., Seattle,
ashington) was used for all analyses.
esults
atient population. Between July 2005 and June 2007, a
otal of 607 patients undergoing PCI for uLMCA stenosis
ere enrolled and randomly assigned to receive either PES
r SES (Fig. 1). Table 1 shows the baseline characteristics of
atients, which were comparably distributed between the 2
reatment groups. One-fourth of the patients were women,
nd nearly 30% of them had diabetes. One-half of the
atients in both groups presented with acute coronary
yndrome. The proportion of high-risk surgical candidates
as similar in both groups: Parsonnet score 15 in 35.0%
f patients assigned to receive PES and 29.2% of patients
ssigned to receive SES (p  0.12); EuroSCORE 6 in
7.0% and 31.8%, respectively (p  0.17). Therapy at
ischarge was virtually the same for both groups, with
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May 12, 2009:1760–8 DES for Left Main Coronary Artery Lesionspproximately 95% of patients receiving statin and beta-
locker drugs, as shown in Table 1.
Two-thirds of the patients had 3-vessel disease, and in
early 15% the dominant right coronary artery was oc-
luded. The localization of stenosis within the LMCA area
as virtually the same, with 63% of patients having distal
Figure 1 Study Flow Chart
CABG  coronary artery bypass graft; uLMCA  unprotected left main coronary art
Baseline Characteristics and Therapy at Discha
Table 1 Baseline Characteristics and Thera
Characteristics P
Age, yrs
Women
Arterial hypertension
Hypercholesterolemia
Diabetes mellitus
Insulin-requiring
Oral drug-requiring
On diet only
Current smoker
Body mass index, kg/m2
Acute coronary syndrome
History of myocardial infarction
History of percutaneous coronary intervention
Creatinine serum level, mg/dl
Malignancies
Parsonnet score
EuroSCORE
Therapy at hospital discharge
Statins
ACE inhibitors
AT1 receptor blockers
Beta-blockersData are presented as n (%) or mean  SD.
ACE  angiotensin-converting enzyme; AT1  angiotensin II type 1; PES tenosis in both groups. Implantation of the assigned stent
as successful in all patients. Both groups were well-
atched with regard to procedural characteristics as shown
n Table 2. No differences were observed in the PCI
echnique used for uLMCA stenting: 50% of patients in
oth groups underwent single stenting, and 49% of patients
Discharge
 302) SES (n  305) p Value
 10.1 69.3 9.34 0.74
(25) 62 (20) 0.13
(70) 209 (69) 0.79
(78) 229 (75) 0.32
(30) 86 (28) 0.66
(10) 23 (8) 0.24
(14) 41 (13) 0.87
(6) 22 (7) 0.43
(10) 30 (10) 0.86
 4.1 27.1 3.8 0.74
(44) 121 (40) 0.31
(25) 84 (28) 0.57
(46) 153 (50) 0.31
 0.81 1.06 0.52 0.81
(9.9) 31 (10.2) 0.92
 9.8 12.0 9.1 0.42
 3.4 4.4 3.2 0.25
(95) 291 (95) 0.99
(87) 261 (86) 0.59
(11) 39 (13) 0.48
(98) 298 (98) 0.79ery.rge
py at
ES (n
68.8
77
210
237
90
31
42
17
31
27.0
132
77
139
1.08
30
12.8
4.7
288
263
33
296paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s).
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DES for Left Main Coronary Artery Lesions May 12, 2009:1760–8ssigned to receive PES versus 48% of patients assigned to
eceive SES underwent culotte-stenting (p  0.89). Sixty-
ix percent of patients with distal lesions received 2 stents;
8% of them received implantation with the “culotte”
echnique. Final kissing balloon inflation was used in 50% of
ll patients but in 90% of those patients who received 2
tents. Rotational atherectomy was used in 1% of the
ases. Intravascular ultrasound was not used in this study,
ither during the procedure or at follow-up. Additional PCI
f at least 1 lesion outside the LMCA area was performed
n 63 patients (21%) assigned to receive PES and in 65
atients (21%) assigned to receive SES (p  0.89).
linical outcomes. The incidence of definite stent throm-
osis was 0.3% in the PES group (1 patient had stent
hrombosis 10 days after PCI while taking dual antiplatelet
herapy) and 0.7% in SES group (1 patient had stent
hrombosis 3 days and another 10 days after PCI, both
hile taking dual antiplatelet therapy) (p  0.57). All 3
ases of stent thrombosis were associated with ST-segment
levation MI and death, shortly after successful recanaliza-
ion in 2 and failed intervention in 1. There was only 1
robable stent thrombosis in the SES group. That consisted
f 1 sudden death at day 19 after enrollment.
Clinical follow-up at 12  1 month was available for all
atients, and respective outcomes are shown in Table 3. No
ignificant differences were observed between the 2 stent
roups in terms of death, MI, stroke, or repeat revascular-
zation within 30 days. The incidence of the primary end
oint of death, MI, and TLR was 13.6% (95% confidence
nterval [CI]: 12.2% to 20.4%) in the PES and 15.8% (95%
Angiographic and Procedural Characteristics
Table 2 Angiographic and Procedural Chara
PES (n
Left ventricular ejection fraction, % 53.4
Vessel size of left main artery, mm 3.83
Coronary artery dominance
Right 236
Left 41
Balanced 25
Three-vessel disease 213
Occluded right coronary artery 41
Trifurcation morphology 75
Localization of left main lesion
Ostium 37
Midshaft 74
Distal 191
Stenting technique
Single stenting 148
T-stenting 5
Culotte stenting 149
Kissing balloon technique 152
Intra-aortic balloon pump 4
Abciximab administration 26
Bivalirudin administration 46
Data are presented as n (%) or mean  SD.
Abbreviations as in Table 1.I: 10.2% to 18.1%) in the SES group. This corresponds to 1difference of 2.2% with an upper 95% CI of 2.7%.
ccordingly, the null inferiority hypothesis for the PES was
ejected (p  0.001). Assignment to the paclitaxel-eluting
tent group was thus associated with an RR of the primary
nd point of 0.85 (95% CI: 0.56 to 1.29). The incidence of
eath, MI, and stroke within 1 year was 5.0%, 5.0%, and
.7%, respectively, in patients assigned to receive PES and
.6%, 4.6%, and 1.0%, respectively, in patients assigned to
eceive SES. The cumulative incidence of death, MI, and
troke was similar in both groups: 9.6% in the PES
nd 10.2% in the SES group (RR: 0.95; 95% CI: 0.57 to
.57, p  0.83).
The primary end point was also analyzed in the pre-
pecified subgroups of patients defined by diabetes and
urgical risk status (Fig. 2). Among diabetic patients, the
ncidence of the primary end point was 13.5% in the PES
nd 19.8% in the SES group (RR: 0.65; 95% CI: 0.31 to
.36, p  0.26); in patients with Parsonnet score 15 the
ncidence of the primary end point was 17.0% in the PES
nd 26.0% in the SES group (RR: 0.62; 95% CI: 0.27 to
.40, p  0.25); in patients with EuroSCORE 6 the
rimary end point rate was 21.5% in the PES and 24.8% in
he SES group (RR: 0.81; 95% CI: 0.46 to 1.42, p  0.47).
At 2 years no differences were observed regarding
aplan-Meier estimates of mortality, MI, and stroke, with
0.4%, 5.4%, and 2.1%, respectively, in patients assigned to
eceive PES and 8.7%, 4.6%, and 1.5%, respectively, in
atients assigned to receive SES. Four patients (1.3%) in
ach group experienced a Q-wave MI. The cumulative
ncidence of death or MI was 14.5% in the PES group and
tics
) SES (n  305) p Value
54.4 12.5 0.68
3.78 0.55 0.20
0.56
224 (80)
33 (11)
28 (9)
225 (74) 0.37
46 (15) 0.60
74 (24) 0.85
0.82
33 (11)
79 (26)
193 (63)
0.89
154 (51)
4 (1)
147 (48)
151 (50) 0.84
4 (1) 0.99
33 (11) 0.34
50 (16) 0.69cteris
 302
12.8
0.56
(78)
(14)
(8)
(71)
(14)
(25)
(12)
(25)
(63)
(49)
(2)
(49)
(50)
(1)
(9)
(15)1.7% in the SES group (RR: 1.20; 95% CI: 0.76 to 1.90,
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May 12, 2009:1760–8 DES for Left Main Coronary Artery Lesions 0.43). The cumulative incidence of death, MI, or stroke
as 15.9% in the PES group and 12.3% in the SES group
RR: 1.25; 95% CI: 0.81 to 1.94, p  0.31) Moreover, no
ifferences were observed in the combined incidence of
eath, MI, and TLR, with 21.3% in patients assigned to
eceive PES and 20.6% in patients assigned to receive SES
RR: 1.01; 95% CI: 0.70 to 1.44, p  0.96) (Fig. 3). Three
atients in each group (1.0%) underwent CABG for
ymptomatic restenosis. The incidence of TLR was also
imilar in the 2 groups: 9.2% for the PES group and 10.7%
or the SES group (RR: 0.82; 95% CI: 0.48 to 1.40,
 0.47). No new cases of stent thrombosis were observed
ver and above those that occurred during the first 30 days
fter randomization.
ngiographic restenosis. The median (interquartile range)
nterval to repeat coronary angiography was 196 (141 to
14) days. Follow-up angiography data were available for
57 (85.1%) patients in the PES group and 273 (89.5%)
Clinical Outcome
Table 3 Clinical Outcome
PES (n  302)
30 days
Definite stent thrombosis 1 (0.3)
Probable stent thrombosis 0
Death 3 (1.0)
MI 13 (4.3)
Stroke 2 (0.6)
CABG 0
Repeat PCI 1 (0.3)
TLR 1 (0.3)
Death or MI 15 (5.0)
Death, MI, or stroke 17 (5.6)
Death, MI, or TLR 15 (5.0)
1 yr
Death 15 (5.0)
MI 15 (5.0)
Stroke 5 (1.7)
CABG 3 (1.0)
Repeat PCI 16 (5.5)
TLR 19 (6.5)
Death or MI 26 (8.7)
Death, MI, or stroke 29 (9.6)
Death, MI, or TLR 41 (13.6)
2 yrs
Death 28 (10.4)
MI 16 (5.4)
Stroke 6 (2.1)
CABG 3 (1.0)
Repeat PCI 22 (8.2)
TLR 25 (9.2)
Death or MI 40 (14.5)
Death, MI, or stroke 44 (15.9)
Death, MI, or TLR 59 (21.3)
Data are presented as n (%); percentages are Kaplan-Meier estimates
CABG  coronary artery bypass graft surgery; CI  confidence inte
RR  relative risk; TLR  target lesion revascularization; other abbrevatients in the SES group (p  0.10). cThe incidence of binary angiographic restenosis—the
econdary end point of the study—was not significantly
ifferent between the 2 stent groups: 16.0% (41 of the 257
atients) in the PES group and 19.4% (53 of the 273
atients) in the SES group (RR: 0.82; 95% CI: 0.57 to 1.19,
 0.30). Restenosis was localized in the distal part of the
eft main area in all but 1 patient in the PES group and in
ll patients in the SES group. In the only patient without a
istal restenosis, this complication was of ostial location.
iscussion
his study has 2 unique features: it is the largest specifically
esigned randomized study on the interventional treatment
f uLMCA lesions and the first comparative evaluation in
his lesion type of 2 different DES platforms that are
ommonly used in other types of coronary disease. The lack
f an additional group treated with CABG obviously limits
irect comparisons with this treatment option, which is
(n  305) RR (95% CI) p Value
(0.7) 0.50 (0.04–5.29) 0.57
(0.3) 0.32
(1.6) 0.60 (0.14–2.49) 0.48
(3.6) 1.19 (0.54–2.66) 0.66
(0.3) 2.02 (0.19–21.27) 0.56
0
(0.7) 0.50 (0.04–5.29) 0.57
(0.7) 0.50 (0.04–5.29) 0.57
(4.6) 1.08 (0.52–2.24) 0.83
(4.9) 1.14 (0.57–2.29) 0.70
(4.6) 1.08 (0.52–2.24) 0.83
(6.6) 0.74 (0.38–1.45) 0.39
(4.6) 1.08 (0.52–2.24) 0.83
(1.0) 1.67 (0.40–6.90) 0.47
(0.7) 1.48 (0.25–8.78) 0.66
(7.8) 0.67 (0.36–1.27) 0.23
(7.8) 0.81 (0.44–1.47) 0.49
(9.5) 0.90 (0.53–1.53) 0.71
(10.2) 0.95 (0.57–1.57) 0.83
(15.8) 0.85 (0.56–1.28) 0.44
(8.7) 1.14 (0.66–1.95) 0.64
(4.6) 1.15 (0.56–2.36) 0.69
(1.5) 1.52 (0.43–5.34) 0.51
(1.0) 1.00 (0.20–4.97) 0.99
(10.7) 0.68 (0.36–1.27) 0.23
(10.7) 0.82 (0.48–1.40) 0.47
(11.7) 1.20 (0.76–1.90) 0.43
(12.3) 1.25 (0.81–1.94) 0.31
(20.6) 0.98 (0.70–1.44) 0.96
 myocardial infarction; PCI  percutaneous coronary intervention;
as in Table 1.SES
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5
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4
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DES for Left Main Coronary Artery Lesions May 12, 2009:1760–8mong patients with uLMCA lesions. The main findings of
he present study were that DES are associated with an
xcellent procedural success rate and are safe and efficacious
n a large cohort of relatively nonselected patients with
MCA disease. In addition, there was no significant dif-
erence in outcomes achieved with the 2 DES types: the
ES and the SES.
On the basis of results from a subgroup analysis confined
o a subset of 91 patients with uLMCA disease from the
andomized Veterans Administration Coronary Bypass Sur-
ery Cooperative study (21) and 10-year follow-up data of
50 patients with uLMCA disease included in a meta-
nalysis of 7 randomized trials (22), CABG has been
ecommended as the standard treatment for such disease in
ontemporary guidelines (14).
The use of PCI has been limited to emergency or
alliative indications in clinical situations considered unsuit-
ble for surgery. Furthermore, the predilection of uLMCA
isease for location in or close to the bifurcation makes PCI
real challenge for interventional cardiologists independent
f the device type used (23). In our study, two-thirds of the
atients presented with multivessel disease, more than 60%
f them had distally localized lesions, and 50% of them
nderwent double stent implantation with culotte tech-
ique. Yet, stenting was successful in all patients, with a very
nfrequent use of intra-aortic balloon counterpulsation sup-
ort. Usage of DES in bifurcation lesions has been reported
o increase the rate of reduced coronary flow and peri-
nterventional thrombotic complications (24). This was not
Figure 2 1-Year Incidence and Relative Risk of the Primary End
Myocardial Infarction, and Target Lesion Revasculariz
Relative risks associated with the use of paclitaxel-eluting stents (PES) as compar
with sirolimus-eluting stents (SES) are shown with their 95% confidence intervals (bserved in our study cohort. Systematic use of 600-mg tlopidogrel pre-treatment in our study might be 1 plausible
xplanation for this.
The low incidence of definite and probable stent throm-
osis in our study and previous registries (25) supports the
ong-term safety of DES in uLMCA lesions. Moreover, the
ortality rates of 1.3% at 30 days, 5.8% at 1 year, and 9.5%
t 2 years compare very favorably with the ones observed in
atients undergoing surgery for uLMCA disease. Old
etrospective surgery studies have demonstrated mortality
ates from 1.7% to 7.0% in-hospital and from 6% to 14%
t 1 year (26–28). In the recently published MAIN-
OMPARE (Revascularization for Unprotected Left Main
oronary Artery Stenosis: Comparison of Percutaneous
oronary Angioplasty versus Surgical Revascularization)
egistry, 3-year mortality was 8.3% among 1,138 consecu-
ive patients who underwent CABG (13,29). Mortality
ndings from the present study compare well with these
atter results, particularly when bearing in mind that the
opulation of the MAIN-COMPARE registry was younger
62 years of age), presented less frequently with a history of
I (15%), had better left ventricular function (ejection
raction 62%), and had lower frequency of both multivessel
isease (60%) and distal uLMCA lesion location (52%), as
ompared with the present study population. Moreover, the
ortality rate at 1 year of 12.0% in high-risk surgical
atients is also very similar to previously published data
30,31).
Notwithstanding the value of long-term outcomes after
CI, which are comparable to those shown for CABG in
t of Death,
in Pre-Specified SubgroupsPoin
ation
ed
CIs).erms of hard safety end points such as mortality, death, and
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May 12, 2009:1760–8 DES for Left Main Coronary Artery Lesionstroke, the frequency of need for repeat revascularization
emains a constant concern with PCI techniques (2). Com-
elling evidence from large registries and randomized stud-
es has demonstrated a consistent reduction in restenosis
ates and need for repeat revascularization with PES and
apamycin-eluting stents (on the order of 70% to 80%)
ompared with BMS in lesions located outside the left main
essel (8,32). The only randomized study comparing
aclitaxel-eluting stents with BMS in uLMCA lesions (33)
howed a 2% revascularization rate with PES versus 16%
ith BMS. A systematic review of more than 1,200 patients
ith uLMCA lesions demonstrated a low revascularization
ate of 6.5% with DES at a median of 10 months of
ollow-up (31). Other investigators have reported cumula-
ive rates of TLR of 18.8% at 1 year and 20.7% at 3 years
34). The overall 2-year cumulative incidence of TLR of
0% (with CABG in only 1% of patients) observed in the
resent study emphasizes the efficacy of DES for uLMCA
Figure 3 2-Year Adverse Event Rates
in the PES and SES Groups
(A) Mortality. (B) Composite of death, myocardial infarction, and target lesion
revascularization. RR  relative risk; other abbreviations as in Figure 2.esions. The impact of stenting technique in the subsequentisk of restenosis is not known for uLMCA lesions. How-
ver, the results achieved in this study might not be
xtrapolated to situations in which other stenting techniques
re used to cover uLMCA lesions.
Interestingly, we did not see any significant difference in
he risk of restenosis between the 2 DES used: PES and
ES. This is in contrast with some previous studies and
eta-analyses on lesions situated outside the left main
oronary artery showing a higher risk of restenosis with PES
11,35). The difference might be explained by the larger size
f the left main coronary artery, which might accommodate
larger degree of neointima formation without significant
umen obstruction (36). An additional factor might have
een the availability of PES in sizes larger than SES, which
s an advantage for large left main vessels. We should
cknowledge that inclusion of protocol-mandated follow-up
ngiography might have exaggerated the TLR rates in both
roups. Conversely, follow-up angiography should be re-
arded as an important precautionary measure to enable
imely treatment of an asymptomatic left main artery
estenosis in consideration of the still-limited experience
ith DES in uLMCA lesions. Importantly the overall
dverse event rates observed in our study are comparable to
hose observed in the subgroup of patients with uLMCA
esions treated either with DES or CABG as part of a recent
andomized trial comparing these 2 strategies in patients
ith left main or 3-vessel coronary artery disease (37). The
ower-than-expected event rate in the present study inevi-
ably reduces the power of the trial; yet, it still remains the
argest randomized trial dedicated to the interventional
reatment of LMCA disease.
onclusions
he use of DES in uLMCA lesions in relatively unselected
atients is feasible, safe, and effective. Two approved and
ommonly used DES platforms, the PES and SES, provide
imilar clinical and angiographic outcomes in this important
atient group.
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